ArticleInternational journal of clinical and experimental pathology2026
Integrated bioinformatics and immunohistochemical analysis reveal that S100A16 is correlated with mutational burden, immune evasion, and
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionS100A16, a member of the S100 family of calcium-binding proteins, is involved in the progression of several malignancies. However, its specific mechanism of action in gastric cancer is not completely understood. The objective of this study, therefore, was to examine the correlation between the expression of S100A16 and clinicopathological characteristics and to investigate its potential significance in gastric adenocarcinoma.
methodsS100A16 messenger RNA (mRNA) expression in stomach cancer was analyzed using bioinformatics to determine the link(s) between diagnostic utility, prognostic importance, tumor mutational burden (TMB), and immune cell infiltration of S100A16 mRNA in patients with gastric cancer.
resultsS100A16 mRNA expression was elevated in gastric adenocarcinoma, particularly in samples with microsatellite instability. S100A16 mRNA demonstrated significant diagnostic efficacy for gastric cancer. There was a strong correlation between S100A16 mRNA expression and TMB, and a negative correlation between S100A16 mRNA levels and Tumor Immune Dysfunction and Exclusion (i.e., "TIDE") score. Immunohistochemistry results revealed significant differences in S100A16 expression across groups with various histological differentiation in gastric cancer. There was a positive association between S100A16 and P53 expression in those with gastric cancer.
conclusionsThere was significant upregulation of S100A16 in gastric adenocarcinoma, which was associated with the level of differentiation and expression of P53. S100A16 may play a role in gene mutations, microsatellite status, and TMB in gastric adenocarcinomas. In addition, S100A16 may be associated with the ability of gastric adenocarcinoma cells to evade the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.